“It's safe to keep taking GLP-1s during pregnancy.”
What the evidence shows
Both semaglutide and tirzepatide labels state these drugs are not recommended during pregnancy: weight loss isn't a goal in pregnancy, animal reproduction studies showed potential fetal harm at clinically relevant exposures, and human data were essentially absent at approval. The standing medical advice is consistent — if pregnancy occurs or is suspected, don't take the next dose and contact the prescriber promptly. Because these drugs clear slowly, the semaglutide label specifies discontinuing at least 2 months before a planned pregnancy so it has time to clear.
What we still don’t know
The newest human exposure data are more reassuring than the animal studies feared — cohorts of first-trimester exposure (Cesta et al., JAMA Internal Medicine 2024; Dao et al., BMJ Open 2024) have not shown a clear increase in major birth defects — but these studies are observational, modest in size, and cover early inadvertent exposure only, not deliberate use throughout pregnancy. 'No signal so far in small studies' is not the same as 'proven safe.'
Why the claim misleads
'Safe to keep taking' inverts the actual guidance. The reassuring first-trimester data are meant to calm someone who was exposed before they knew they were pregnant — not to license continuing the drug on purpose. The established position is that these medicines are stopped in pregnancy and planned around before conception, a decision to make with an obstetric clinician rather than a website.
Graded by The Peptide Era · evidence, not hype